Global Regenerative Trade

Global Biomedikal is the new Turkish distributor of Arteriocyte’s products

Global Biomedikal is the new Turkish distributor of Arteriocyte products

 Global Biomedikal, one of the top distributors of regenerative medical products in Turkey, has announced that it has entered into an agreement to become the local distributor for Arteriocyte, a leading clinical stage biotechnology company, whose products include platelet rich plasma (PRP) kits. The Turkish distributor agreed to complete half a million in sales for the first year of distribution.

Mr. Semih Soylu from Global Biomedikal invited the Global OrthoBiologic team together with Dr. Dzihan Abazovic to conduct medical trainings in Liv Hospital, Turkey. The training was very successful and impressive. The introduction of the innovative Magellan Technology and the proprietary BMAC with the bone marrow aspiration cannula was the main topic of the presentation. The audience in the operating room was quite impressed by Dr. Abazovic and his knowledge of the procedures.

The GOB Team is also pleased to announce that after a successful meeting with Professor Erdal Karaoz, he is now part of our scientific board.

Professor Erdal Karaoz is the Managing Director of Regenerative Medicine Research & Manufacturing Center at LivMedCell. Professor Karaoz received his Masters degree from Dicle University in Histology-Embryology in 1989 and his PhD from Gazi University in Histology-Embryology in 1994. He became an Associate Professor at Suleyman Demirel University in 1996 and a Professor at Suleyman Demirel University in 2002. From 2003 to 2014, he was the Founding Director of Stem Cell and Gene Therapies Research and Application at Kocaeli University. During that same time, he was also the Founding Chairman of the Stem Cell Division at the Institute COD Health Sciences. Professor Karaoz taught at Joslin Diabetes Center of Harvard Medical School in 2005.

Professor Karaoz is the author of over 100 national and international articles and 4 books. He is the recipient of 36 awards. He is a member of the Turkish Hematology Association; European Association for Cancer Research; International Cellular Medicine Society; Organ, Tissue, and Cell Transplantation Society; and Stem Cell and Cell Therapy Association, among others.

On the last day of visit, our team had a presentation in front of Dr. Ahmet Murat Bulbul from the Istanbul Medipol University. He was extremely impressed by the BMAC and he has invited us for training in May.

About Global OrthoBiologic Inc.

Global OrthoBiologic Inc., based in Miami Florida, develops, markets, and globally distributes new and innovative products in the field of Regenerative Medicine. Global OrthoBiologic Inc. was established to promote and distribute groundbreaking medical technologies for use in therapies that significantly enhance the body’s natural healing ability. During the last decade, the company has developed extensive experience in the most advanced medical device industries and technologies. Global OrthoBiologic Inc. consults not only with startup biotech and medical technology companies, but also with mature companies that wish to better develop their international business. In the past several years, the company’s emphasis has been focused exclusively on Regenerative Medicine, such as stem cell technologies, products, and therapies. Global OrthoBiologic Inc. has built a comprehensive network of experts and country distributors in Europe, South America, Middle East, Asia, and Australia. Global OrthoBiologic Inc. has additional sales offices in Sofia, Bulgaria and Dubai, UAE, as well as a distribution center in Amsterdam, Netherlands.

About Global Biomedikal

Global Biomedical Product Portfolio

  • Innovative Technologies
  • Regenerative Therapies (Cell-Based)
  • Treatments for chronic diseases
Vivostat Logo


The uniqueness of the Vivostat® system is a novel patented biotechnological process that enables reliable and reproducible preparation of autologous Fibrin Sealant or Platelet Rich Fibrin (PRF®) without using cryoprecipitation and without the need for a separate thrombin component.